Gazeta Lodz - Deepinder Goyal’s Temple Wearable Faces Scrutiny Over Scientific Claims

Pre-orders for Temple, a forehead-worn wearable device priced at Rs. 85,000, opened on November 1, immediately triggering a public dispute between the product’s founder and medical professionals. Deepinder Goyal, the co-founder of Zomato and Eternal, faces allegations from doctors that his company has failed to provide the scientific evidence required to support its claims about the device’s capabilities.

The controversy centers on the device’s ability to measure brain activity and heat dissipation. Temple is an adhesive sensor worn on the side of the forehead. According to the company, its primary metric, called Entropy, measures how hard the body works to shed heat by reading data from the temple. A second metric, BrainFlow, is designed to track blood flow to the brain.

Dr. Cyriac Abby Philips, a hepatologist known online as TheLiverDoc, has led the criticism against the product. On November 4, he questioned why Goyal was selling the device on pre-order before proving its efficacy. "So why are you already selling Temple device on preorder, that has not been proven to work for any of the claims made, for Rs. 85,000? Usually people sell devices that work. Do explain," Philips wrote.

Goyal responded on November 5 in a post titled "Dear Concerned Indian Doctors." He defended the company’s approach by comparing it to other wearable technology firms, noting that many start with internal studies before publishing peer-reviewed data. He cited Whoop, which launched its band in 2015 with validation following years later. Goyal stated that Temple holds itself to a higher standard and that pre-prints of their research are forthcoming.

"Most wearable companies start with internal studies. Whoop shipped its band in 2015, and the first published validation followed a few years later. We hold ourselves to a higher standard; pre-prints are a step prior to peer reviewed publications, and they are coming up," Goyal wrote. He also highlighted that the company had spent $30 million on the project, with $20 million coming from his own pocket.

However, Philips rejected these defenses. On November 9, he argued that the sensor’s location is scientifically flawed for its intended purpose. "Instead, Temple only reads a surface artery on the forehead that supplies the scalp and face, which flushes with heat or exercise independently of the brain," he wrote. He added that the device cannot separate blood flow in the brain from blood flow in the scalp.

Philips also criticized the company’s recent publications. He described a heart-rate study as an "unreviewed, in-house white paper funded, run, and analyzed entirely by Temple Private Limited." He noted that none of the papers tested Entropy, which Goyal has positioned as the device’s unique selling point. In earlier posts, Philips alleged data falsification, though these remain allegations not yet verified by an independent body.

The dispute has raised questions about the regulatory gap between fitness trackers and medical devices. Nikhil Pahwa, founder of MediaNama and an investor in Zomato, argued on November 10 that regulators should intervene. "I think India’s Health Ministry / Central Drugs Standard Control Organization which regulates medical devices should look into this," Pahwa wrote. He suggested that the controversy highlights a regulatory gap that some fitness devices exploit.

Pahwa also urged investors to engage with Goyal using scientific evidence rather than personal attacks. "This should force us to look at the gap between medical devices and fitness devices... especially since investor money is now involved," he added.

Goyal has denied that Temple is a medical device, classifying it strictly as a fitness and AI device. He stated that the company has obtained necessary clearances from regulatory bodies where required but did not provide further details. "Social media is not the regulator for Temple. Wherever we need regulatory clearances, we will have them before we make any claim needing them," he said.

The controversy also involves allegations of inadequate disclosure regarding influencer support. On November 8, Philips wrote to podcaster Ranveer Allahbadia, who had defended Temple on social media, asking him to disclose his financial interests. Philips alleged that Allahbadia is an angel investor in Temple’s $54 million funding round, though the size of his stake has not been made public.

Another influencer, Raj Shamani, hosted Goyal for a four-hour podcast where Temple was discussed alongside other topics. According to Inc42, Shamani holds a 0.03% stake in Temple. Goyal denied asking anyone to post content online for money, posting a screenshot of a Discord conversation where he allegedly asked someone to "amplify" tweets.

The origins of Temple trace back to November 2025, when Goyal published the "Gravity Ageing Hypothesis," suggesting that gravity’s pull on blood flow to the brain contributes to aging. He later apologized for presenting this idea as a scientific fact, admitting he had "miscommunicated" and compressed years of research into a dramatic social media reveal.

Criticism of the project began in January when Philips described Temple as promoting an "ancient, already debunked gravitational theory of ageing." Goyal responded at the time by stating that no commercial announcements or data releases had occurred yet. "We will share all the science if and when we decide to sell the Temple," he said.

In February, Goyal announced that Temple had raised $54 million at a post-money valuation of approximately $190 million. The company later acquired London longevity practice Longevous, bringing on Dr. Robert Mohr as chief medical officer and Dr. Avi Roy as head of science. In September, Goyal posted two preprints testing BrainFlow against Transcranial Doppler ultrasound in healthy adults and near-infrared spectroscopy in 60 participants.

By November 5, Goyal had shifted the product’s description from a brain-tracking device to a fitness tracker. "Temple is a fitness tracker, and wellness device. We are not a medical device," he wrote. On November 8, he posted a ten-point response reiterating that no medical claims were made and that BrainFlow was merely the starting point of the project.

The debate continues over where to draw the line between fitness tracking and clinical diagnostics. While Goyal argues that pre-prints are a valid step toward validation, critics maintain that selling an expensive device based on unverified claims misleads consumers and exploits regulatory loopholes.

I.Wroblewski--GL